Fewer than 10% of individuals who could benefit from obesity jabs including Wegovy are able to get them, states the global health agency as it releases its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our new guidelines affirms that excess weight is a lifelong illness that can be treated with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key hurdles to widespread availability to the injections that can help people shift considerable weight, says the organization.
Weight-Loss Drug Shortage
Even in the current most favorable case, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the WHO.
The advice encourages countries and companies to increase access, by approaches like voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Weight-Loss Drugs Operate
These medications imitate a natural hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so users consume fewer calories.
Patients typically see weight reduction after several weeks of beginning the regular doses.
Research points to users may regain a significant portion after a year of halting the treatment, when their usual appetite resume.
To be carrying excess weight elevates your likelihood for experiencing health problems, like diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
